The research team, led by co-first authors Mica C. G. Williams and Lenique K. L. Huggins of Yale’s Department of Dermatology, together with colleagues in medical oncology including Jill Lacy and Jacquelyne Gaddy, and senior author Jonathan Leventhal, set out to test whether a brief educational intervention could improve what patients know about cutaneous toxicities. Their focus was a population that has often been overlooked in oncodermatology research: patients undergoing treatment for gastrointestinal cancers, a group that includes malignancies of the colon, rectum, stomach, pancreas, liver, and esophagus. According to global burden analyses cited by the authors, gastrointestinal cancers collectively represent one of the largest sources of cancer incidence and mortality worldwide, making any strategy that improves their care potentially far-reaching.

Cutaneous toxicities are among the most common adverse effects of modern cancer therapy, and their spectrum is broad. Traditional cytotoxic chemotherapy can cause hand-foot syndrome, diffuse hair loss, nail discoloration, and increased photosensitivity. Epidermal growth factor receptor inhibitors, frequently used in colorectal cancer, classically produce an acneiform eruption affecting the face and trunk, along with paronychia and xerosis. Immune checkpoint inhibitors, which have transformed the treatment landscape for many GI malignancies, can trigger immune-related adverse events in the skin ranging from mild vitiligo-like depigmentation and eczematous eruptions to severe, potentially life-threatening blistering disorders such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Prior work by some of the same Yale investigators has shown that acute dermatologic adverse events can lead to interruptions or delays in anticancer therapy, and that the presentation of these events may differ in patients with skin of color, complicating recognition and timely treatment.

Despite this heavy burden, the Yale team recognized that patient education about skin, hair, and nail side effects has lagged behind education about other, more widely discussed toxicities such as nausea or fatigue. Their earlier studies, including a 2023 educational intervention for women with breast cancer and skin of color and a 2024 survey of patient preferences in a tertiary oncodermatology clinic, indicated that patients wanted accessible, readable materials about dermatologic side effects. The new study extended that line of inquiry to gastrointestinal cancer patients, a group for whom no comparable educational tool had been formally evaluated.

The study was conducted at a tertiary academic center and enrolled 51 patients actively undergoing treatment for gastrointestinal cancers. The demographic profile of the cohort reflects the realities of GI cancer epidemiology: 71.0 percent of participants were older than 60 years, 76.5 percent identified as white, and the majority had obtained at least some college education. Gender distribution was nearly balanced, with 56.9 percent identifying as female and 43.1 percent as male. Each participant reviewed an educational pamphlet specifically designed to describe the cutaneous, hair, and nail toxicities associated with GI cancer treatments, and then completed survey questions assessing their knowledge both subjectively, through self-reported confidence, and objectively, through knowledge-based questions.

Forty-eight of the 51 patients completed both the intervention and the surveys, a high completion rate that underscores the feasibility of the approach. The results were clear: after reviewing the pamphlet, patients demonstrated statistically significant improvement in both their subjective and objective knowledge assessments. In practical terms, patients not only felt better informed about what to watch for on their skin, scalp, and nails, but they also answered more knowledge questions correctly, indicating genuine learning rather than a mere placebo effect of reassurance. The authors conclude that an accessible educational tool of this kind can effectively improve patients’ understanding of the cutaneous toxicities arising from oncologic treatments for GI cancers.

The technical significance of this finding lies in its implications for supportive oncology. Dermatologic adverse events are frequently underreported by patients, who may assume that skin changes are trivial compared with their cancer diagnosis, or who may not know which changes warrant a call to their oncology team. Yet early recognition matters: prompt dermatologic evaluation can prevent mild toxicities from escalating, reduce unnecessary treatment interruptions, and in the case of immune-related eruptions, may even serve as an early signal of immune activation. By arming patients with baseline knowledge before or during therapy, a low-cost pamphlet functions as a distributed early-warning system, extending the reach of the small number of oncodermatology specialists into infusion suites and oncology clinics everywhere.

The study also fits into a broader movement within dermatology to leverage simple, scalable educational formats. Narrative reviews of patient education in dermatology have highlighted the growing role of digital and social media channels, but printed materials retain distinct advantages for the demographic most affected by GI cancers: older adults, who may prefer tangible resources and who are less likely to seek dermatologic information online. The Yale pamphlet model, now validated in breast cancer, gynecologic cancer, and gastrointestinal cancer populations, offers a replicable template that other institutions could adapt, potentially with versions tailored to patients with skin of color, in whom cutaneous toxicities may present with different morphologies and pigmentation patterns.

Limitations acknowledged by the design itself warrant careful interpretation. The cohort was relatively small, with 48 completers, and was drawn from a single tertiary academic center with a predominantly white, relatively well-educated sample, raising questions about generalizability to more diverse populations and to community oncology settings, where the majority of cancer care is actually delivered. The study measured short-term knowledge gains rather than long-term retention or downstream clinical outcomes such as reduced emergency visits, fewer treatment delays, or improved quality of life. The authors also note that no datasets were generated or analyzed beyond the survey data reported. Nonetheless, the ethical framework of the study was rigorous: it was approved by the Yale University Institutional Review Board, conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent.

What makes this short report resonate beyond its modest size is the elegance of its central message. In an era of increasingly complex cancer therapeutics, where combination regimens of checkpoint inhibitors and targeted agents produce overlapping and sometimes unpredictable toxicity profiles, one of the most effective interventions may not be a new drug but a well-designed piece of paper. For patients with gastrointestinal cancers, understanding that a new rash, fragile nails, or thinning hair is an expected and manageable consequence of treatment, and knowing when to report it, can transform anxiety into agency. The Yale team’s work provides concrete evidence that a brief educational pamphlet can deliver that understanding, and it challenges oncology practices worldwide to make dermatologic patient education a routine, not an afterthought, in the care of people fighting cancer on every front, including the one visible to the naked eye.

Subject of Research: Patient education on cutaneous toxicities of cancer treatment in gastrointestinal cancers

Article Title: An educational intervention on the cutaneous toxicities of cancer treatment among patients with gastrointestinal cancers

Article References: Williams, M. C. G., Huggins, L. K. L., Dukkipati, H., Saeed, S., Lacy, J., Gaddy, J., & Leventhal, J. (2026). An educational intervention on the cutaneous toxicities of cancer treatment among patients with gastrointestinal cancers. Archives of Dermatological Research, 318(1), Article 506. https://doi.org/10.1007/s00403-026-04921-z

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04921-z

Keywords: gastrointestinal cancer, oncodermatology, cutaneous toxicity, patient education, chemotherapy, immune checkpoint inhibitors, skin adverse events, hair loss, nail changes, pamphlet intervention, supportive oncology, dermatology